Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
5.98+0.09 (+1.53%)
At close: 04:00PM EDT
5.98 0.00 (0.00%)
After hours: 04:33PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close5.89
Open5.98
Bid5.34 x 800
Ask6.37 x 800
Day's Range5.73 - 6.15
52 Week Range5.30 - 19.75
Volume704,063
Avg. Volume1,149,762
Market Cap772.197M
Beta (5Y Monthly)1.59
PE Ratio (TTM)9.31
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ORGO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organogenesis Holdings Inc.
    ORGO: Lowering target price to $4.00ORGANOGENESIS HOLDINGS INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results

    CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Results Summary: Net revenue of $98.1 million for the first quarter of 2022, a decrease of 4% (an increase of

  • GlobeNewswire

    Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors

    CANTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointments of Michele Korfin and Gilberto Quintero, Ph.D. to the Company’s Board of Directors, effective May 3, 2022. Ms. Korfin and Dr. Quintero will serve as independent directors of the Compa

  • GlobeNewswire

    Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference

    CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, NuShield®, Novachor™ and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAW

Advertisement
Advertisement